profit from every $100 of sales.
$0$100
The Cooper Companies
$62.65+0.74% today
-12.7% in 1 year
1-year low $53.271-year high $84.32
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $31.78 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What The Cooper Companies sold, what it kept, and what it did with the cash.
Sales went from $3.31 billion in 2022 to $4.09 billion in 2025, with $375 million of profit last year.
SalesProfit
The Cooper Companies handed back 67% of the cash it generated last year.
Buybacks $290M
Free cash flow 2025$434M
Bought back its own shares$290M
Paid as dividends$0
Cash vs. debt$111M vs. $2.5B
The Cooper Companies vs. similar companies
The Cooper Companies grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| The Cooper Companies | 31.8× · Expensive | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads The Cooper Companies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,431 | 2,923 | 3,308 | 3,593 | 3,895 | 4,092 | |
| 1,535 | 1,956 | 2,140 | 2,358 | 2,596 | 2,682 | |
| 312 | 506 | 508 | 533 | 706 | 683 | |
| 453 | 824 | 879 | 886 | 1,072 | 1,044 | |
| 238 | 2,945 | 386 | 294 | 392 | 375 | |
| 1.20 | 14.79 | 1.94 | 1.48 | 1.96 | 1.87 | |
| 63.1% | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% | |
| 12.8% | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% | |
| 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 6,738 | 9,606 | 11,492 | 11,659 | 12,315 | 12,395 |
| Cash | 116 | 96 | 138 | 121 | 108 | 111 |
| Total debt | 1,793 | 1,481 | 2,763 | 2,569 | 2,584 | 2,505 |
| Total liabilities | 2,913 | 2,664 | 4,318 | 4,108 | 4,232 | 4,156 |
| 3,825 | 6,942 | 7,175 | 7,551 | 8,083 | 8,239 | |
| 198 | 199 | 199 | 199 | 200 | 200 | |
| 4.3% | 4.8% | 4.2% | 4.0% | 5.2% | 4.9% | |
| 6.2% | 42.4% | 5.4% | 3.9% | 4.9% | 4.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 487 | 739 | 692 | 608 | 709 | 796 | |
| 310 | 214 | 242 | 393 | 421 | 362 | |
| 176 | 524 | 450 | 215 | 288 | 434 | |
| Dividends paid | 3 | 3 | 3 | 3 | 0 | 0 |
| 48 | 25 | 79 | 0 | 0 | 290 | |
| 38 | 44 | 54 | 62 | 75 | 71 |
Valuation
- 31.8×
- 13.6×
- 3.44
- 1.6×
- 2.9×
- 27.5×
- 13.7×
- 3.6%
- 3.1%
- 0.0%
Profitability
- 65.5%
- 16.7%
- 9.2%
- 15.9%
- 2.5%
- 9.8%
- 2.8%
- 1.9%
- 4.7%
- 4.1%
Growth
- +11.0%
- +9.2%
- +50.5%
- +0.0%
- +0.4%
Financial health
- 3.4×
- 0.30
- 19.7%
- 5.3×
- 1.27
- 0.78
- 0.34
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 42%of 946
Top 31%of 871
Bottom 44%of 563
Bottom 49%of 867
Top 29%of 986
What analysts expect
- Average price target
- $93.86
- Range
- $73.00 – $100.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 5, 2026 | 1.10 | 1.03 | +6.8% |
| Dec 4, 2025 | 1.15 | 1.11 | +3.6% |
| Aug 27, 2025 | 1.10 | 1.07 | +2.8% |
| May 29, 2025 | 0.96 | 0.93 | +3.4% |
| Mar 6, 2025 | 0.92 | 0.91 | +0.7% |
| Dec 5, 2024 | 1.04 | 1.00 | +4.0% |
| Aug 28, 2024 | 0.96 | 0.91 | +5.4% |
| May 30, 2024 | 0.85 | 0.83 | +2.5% |
News
3 Reasons COO is risky and 1 stock to buy insteadYahoo Finance · Oct 31, 2026PC Connection names Matt Zafirovski president and COOSeeking Alpha · Oct 14, 2026Meta’s Justin Osofsky joins Nscale as COO ahead of IPO: BloombergSeeking Alpha · Oct 3, 2026Dynacor names new COOSeeking Alpha · Oct 1, 2026Can Plug Power’s (PLUG) NZ Electrolyzer Win Offset Questions Raised by a COO Exit?Yahoo Finance · Sep 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
55No pass
Philip Fisher
55No pass
Peter Lynch
30No pass
Joel Greenblatt
18No pass
Charlie Munger
41No pass
Terry Smith
42No pass
Questions about The Cooper Companies
Is The Cooper Companies a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the The Cooper Companies AI analysis
What does The Cooper Companies do?
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. It is in Medical - Instruments & Supplies, based in San Ramon, CA, United States, with 15,000 employees.
Does The Cooper Companies pay a dividend?
No. The Cooper Companies does not pay a dividend at the moment; in 2025 it returned $290 million to shareholders by buying back its own shares.
Is The Cooper Companies stock halal?
Yes. The Cooper Companies passes our halal screen: its business is permitted and its debt is 21% of its market value, under the 30% limit. How we check
How has The Cooper Companies stock done over the past year?
Down 12.7% over the past twelve months, to $62.65. It traded between $53.27 and $84.32 and is 25.7% below its high.
Who are The Cooper Companies's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with The Cooper Companies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.